Latest patent settlement keeps Linzess generic at bay till 2030
Under the terms of a settlement, drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD) and Allergan (NYSE: AGN) have granted Aurobindo Pharma (ARBN: BO) a license to market a generic version of Linzess (linaclotide) in the USA – but not until August 5, 2030.
The firms launched patent litigation in response to the Indian generics maker’s abbreviated new drug application (ANDA) seeking approval to market a copy of Linzess prior to the expiration of the companies’ applicable patents.
This is the second patent infringement settlement that Ironwood and Allergan have reached with respect to Linzess, having settled with wholly-owned subsidiaries of India’s Sun Pharmaceutical Industries (BSE: 524715) in January. That agreement stopped the generic from being launched in the USA before February 1, 2031.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze